Sign in to view content

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept

Mark R. Barakat, MD

Video
Published 2022

Related

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Updates from the Field
2019
Episode 13: Long-Term Treatment of Wet AMD by 50+ Anti-VEGF Injections with Dr. Sean Adrean
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022

Category: Pharmacology

See more